Clinical outcomes of ultra-long acting insulin analogues: impact on hypoglycaemia
This session will assess the comparative data on hypoglycaemic profiles of the two current ultra long-acting basal analogue insulins available Toujeo and Degludec outlying the differences benefits and place in therapy.
- Attendees will be able to see the benefits of both Insulins and place in therapies
- Attendees will be helped in the design of local pathways inculcating these insulins
- Attendees will be helped to see the differences and similarities of these two basal insulins
Session organised and remunerated by Sanofi Diabetes
Wednesday 14th November 2018
12:50 - 13:20